Related references
Note: Only part of the references are listed.Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil
Reinaldo de Menezes Martins et al.
VACCINE (2014)
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina
Cristian Biscayart et al.
VACCINE (2014)
Safety profile of the yellow fever vaccine Stamaril®: a 17-year review
Pascale Cottin et al.
EXPERT REVIEW OF VACCINES (2013)
Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010
J. G. Breugelmans et al.
VACCINE (2013)
Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
Mark D. Gershman et al.
VACCINE (2012)
Guillain-Barre syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data
James J. Sejvar et al.
VACCINE (2011)
Short Report: Incidence of Yellow Fever Vaccine-Associated Neurotropic Disease
Thomas Guimard et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2009)
Viscerotropic disease following yellow fever vaccination in Peru
Alvaro Whittembury et al.
VACCINE (2009)
Adverse event reports following yellow fever vaccination
Nicole P. Lindsey et al.
VACCINE (2008)
Aseptic meningitis:: Case definition and guidelines for collection, analysis and presentation of immunization safety data
Terhi Tapiainen et al.
VACCINE (2007)
Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data
James J. Sejvar et al.
VACCINE (2007)
Anaphylaxis:: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Jens U. Rueggeberg et al.
VACCINE (2007)
Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases
Ann W. McMahon et al.
VACCINE (2007)
Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002
Suely Hiromi Tuboi et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2007)
Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events
AY Khromava et al.
VACCINE (2005)
Understanding vaccine safety information from the vaccine adverse event reporting system
F Varricchio et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety
JK Iskander et al.
PEDIATRIC ANNALS (2004)
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX®
S Kitchener
VACCINE (2004)
Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-VAX) in a Phase III multicenter, double-blind clinical trial
TP Monath et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2002)
Advanced age a risk factor for illness temporally associated with yellow fever vaccination
M Martin et al.
EMERGING INFECTIOUS DISEASES (2001)
Share Paper
